CogState (CGS.AX) Hisse Fiyat
CogState Fiyat
CogState, son 19 yılda gelirini yıllık %20,0 artırarak 53,09 M USD seviyesine taşıdı. Hisse başına kâr, son 16 yılda yıllık %8,5 büyüdü. CogState için net marj, %19,1 ile birkaç yıl önceki %16,0 seviyesine göre yükseldi. Bugünkü fiyata göre temettü verimi kabaca %1,19 seviyesine denk geliyor. Temettü dağıtım oranı, kârın yaklaşık %34 düzeyindedir. CogState için 12 aylık konsensüs fiyat hedefi 2,15 USD; bu, hissenin bugünkü fiyatının yaklaşık %10,6 altında bir seviyeye denk geliyor. 6 analistten 5 tanesi hisse için alım öneriyor — genel konsensüs: Al.
CogState hisse senedi fiyatı
CogState iş modeli ve hisse analizi
CogState hakkında sık sorulan sorular
CogState Ltd is a leading provider of cognitive testing services for clinical trials, academic research, and healthcare. The company's business model revolves around using their digital tools and technologies to measure and enhance cognitive function in patients. By collaborating with pharmaceutical companies, academic institutions, and healthcare organizations, CogState Ltd aims to improve patient outcomes and accelerate the development of new treatments. With their expertise and extensive database, CogState Ltd offers customized solutions and prognostic insights to address the cognitive challenges faced in various industries.
CogState Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of CogState Ltd in the market are Cambridge Cognition Holdings PLC, Neurotrack Technologies Inc., and CogniFit Ltd. These companies also specialize in cognitive assessment and provide similar solutions and services. However, CogState Ltd distinguishes itself through its innovative technologies and partnerships, including collaborations with leading pharmaceutical companies. With its strong focus on enhancing the understanding and measurement of cognitive function, CogState Ltd continues to remain competitive in the market and deliver valuable solutions to its clients.
CogState Ltd is a renowned company with a rich history and background. Founded in 1999, CogState specializes in cognitive testing and offers innovative solutions to improve brain health assessment. With its headquarters in Melbourne, Australia, the company has expanded its global presence, serving various sectors including pharmaceuticals, biotechnology, and academic research. CogState has developed cutting-edge technologies and software platforms to deliver accurate and efficient cognitive assessments, benefiting patients, researchers, and professionals worldwide. Known for its advanced cognitive testing methods and commitment to enhancing brain health, CogState Ltd has established itself as a trusted industry leader.
CogState Ltd has achieved several significant milestones in its history. One key achievement is the development and commercialization of its pioneering cognitive testing technology, known as the CogState Computerized Cognitive Assessment Tool (CCAT). This innovative tool is widely utilized in clinical trials and research studies worldwide, enabling precise and objective measurement of cognitive function. Additionally, CogState Ltd has successfully established strategic partnerships with leading pharmaceutical companies, academic institutions, and healthcare providers, facilitating the widespread adoption of its solutions. The company continues to thrive through ongoing research and development, further cementing its position as a global leader in cognitive assessment technology.
CogState Ltd is primarily present in Australia, the United States, and Europe.
CogState Ltd represents a set of core values and a corporate philosophy that drive its operations. The company is committed to innovation, delivering cutting-edge solutions in the fields of cognitive assessment and clinical trials. CogState prioritizes integrity, ensuring transparent and ethical practices in all aspects of its business. With a focus on collaboration, CogState fosters strong partnerships to drive mutual success. The company values dedication to excellence, constantly striving for improvement and delivering high-quality products and services. CogState fosters a customer-centric approach, prioritizing customer satisfaction and delivering tailored solutions. Overall, CogState Ltd embodies a commitment to innovation, integrity, collaboration, excellence, and customer-centricity in its corporate philosophy.
Analistler şu anda CogState hissesi için ortalama 2,15 USD hedef fiyat belirliyor (medyan: 2,15 USD); bu, son fiyata göre -10,6 % anlamına gelir. Konsensüs 6 analist notuna dayanır.
7 analist şu anda CogState hissesini değerlendiriyor: 6 al, 1 tut, 0 sat öneriyor. 2026 için analistler CogState şirketinin 128,65 M USD gelir ve 0,09 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla CogState hissesi 2,14 EUR (2,40 USD) seviyesindedir.
CogState hissesi (CGS.AX) 2 borsada işlem görür, bunlar arasında: ASX (CGS.AX).
CogState Ltd is an innovative company specializing in the development and marketing of cognitive testing solutions. The company offers a wide range of products and services that can be used in the fields of pharmaceutical research, clinical diagnostics, and sports performance optimization. The three main business divisions of CogState Ltd include research and development of cognitive tests, clinical diagnostics and monitoring of patients with neurodegenerative disorders, and solutions for improving sports performance. The company's products are rooted in today's technology, as they are exclusively offered online. They allow for remote diagnosis and supervision of patients, saving time for therapists and improving diagnostic accuracy. The company's proprietary software platform enables researchers to effectively manage their studies and present study results in a concise format. CogState Ltd has a strategy in place to continue offering unique and expanding product offerings, allowing the company to remain a strong competitor in the industry.
beklenen'nin CogState hasılatı 128,65 M USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin CogState karı 16,22 M USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
CogState'nin Fiyat/Kazanç (F/K) oranı şu anda 25,75'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların CogState hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
CogState'nin Fiyat/Satış (F/S) oranı şu anda 3,25'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve CogState hisse senedinin değerleme metriği olarak hizmet eder.
CogState'nin Eulerpool Kalite Puanı 6/10'dur.
CogState'nin ISIN'i AU000000CGS8'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
CogState'nin ticker'ı CGS.AX'dir. Ticker sembolü, CogState hisseleri borsada işlem görmek için kullanılır.
CogState Hissesi
CogState Emsaller Grubu
CogState Ticker
CogState FIGI
CogState'nin tüm temel göstergeleri ve derinlemesine analizi
CogState hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve CogState şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: